We publish our special reports to help tackle the key questions our clients regularly ask us. We combine our expert knowledge with data driven research to encourage discussion and aid the decision-making process.

Our reports focus on a variety of topics and provide in-depth, data-led analysis and commentary to identify trends and answer critical questions.Designed to offer unique insights our aim is to help businesses make strategic commercial decisions aligned to their goals and objectives in vital areas of IP. 

Intelligent insights to support informed choices

EPO Opposition Trends in Engineering, Electronics and Software

EPO Opposition Trends in Engineering, Electronics and Software

In autumn 2020, we analysed more than 8000 opposition cases filed at the European Patent Office (EPO) over the last 12 years, studying the timelines for hundreds of engineering, electronics and software oppositions.

Download here
EPO Opposition Trends in the Life Sciences Sector

EPO Opposition Trends in the Life Sciences Sector

In spring 2019, Mewburn Ellis undertook 350 hours of research, analysing more than 5,000 opposition cases filed at the European Patent Office over the last ten years, studying the timelines for hundreds of life sciences oppositions both before and after the EPO’s opposition streamlining initiative.

Download here
Patent Landscape in Bioinformatics and Digital Health Special Report 2021-2

Patent Landscape in Bioinformatics and Digital Health: a data-driven analysis

The words "digital health", "data driven" and "AI" have been on everyone's lips and in many headlines in the healthcare and life sciences sectors over the last couple of years. We set out to collect data on the patent landscape in the fields of bioinformatics and digital health, to see whether the growth we and our clients see in the field is reflected in the data and whether insights can be gained that will assist in designing better, more informed IP strategies.

Download here
Pharma and Life Sciences Patent Extensions in Europe

Pharma and Life Sciences Patent Extensions in Europe

Over 60 countries provide extensions for pharma and life sciences patents – more than half of them in Europe. They’re incredibly important in helping to compensate for the years of delay in getting a product through clinical trials and regulatory reviews.

Download here
Software Report Mock-Up

Software Inventions: UKIPO and EPO approaches to patent eligibility

It is well-known that it can be challenging to obtain patent protection for inventions relating to software in Europe. Indeed, it is common for software developers to assume that European patent protection is not available for their innovations.

Download here
The IP Guide for the Forward-Looking SME

The IP Guide for the Forward-Looking SME

Whether you are aiming for an exit strategy through investment or acquisition, or to grow and further establish your business, IP can play a key role. Perhaps you have some experience of IP but are you unsure if you're making the most of it? Perhaps you have no experience of IP and would like to understand how you could use it to your advantage?

Download here
Validation Strategies for Pharmaceutical Patents in Europe-1

Validation Strategies for Pharmaceutical Patents in Europe

The decision on where to validate a pharmaceutical European patent is a big one. With costs often precluding an “everywhere” approach for small- to medium-sized companies, research institutions and universities, it is necessary to choose from the long list of available countries. 

Download here

Advice Summary

What does Brexit mean for Trade Marks?

The UK government and EU set out their agreed position on many of the issues related to intellectual property rights in the Draft Withdrawal Agreement. The UK government has also published papers explaining the approach in the event no agreement can be reached. Our consistent advice, which we still consider to be the best course of action, is that in order to protect brands in the EU, it remains appropriate to continue filing trade mark applications at the EUIPO, and that there is no legal necessity for dual filing in the UK.

Some additional information in one line

The UK government and EU set out their agreed position on many of the issues related to intellectual property rights in the Draft Withdrawal Agreement. The UK government has also published papers explaining the approach in the event no agreement can be reached. Our consistent advice, which we still consider to be the best course of action, is that in order to protect brands in the EU, it remains appropriate to continue filing trade mark applications at the EUIPO, and that there is no legal necessity for dual filing in the UK.

Some additional information in one line

The UK government and EU set out their agreed position on many of the issues related to intellectual property rights in the Draft Withdrawal Agreement. The UK government has also published papers explaining the approach in the event no agreement can be reached. Our consistent advice, which we still consider to be the best course of action, is that in order to protect brands in the EU, it remains appropriate to continue filing trade mark applications at the EUIPO, and that there is no legal necessity for dual filing in the UK.

Life Sciences resized

Convert your pending EU trade mark applications into UK trade mark applications FOR FREE!

Britain’s Brexit future may be complex and unclear. But with Mewburn Ellis, protecting your IP need not be. We are managing the process of converting all pending EU trade mark applications into UK trade mark applications for free.

Find out more
Forward Magazines Overalpping

Mewburn Ellis

FORWARD MAGAZINE

Mewburn Ellis Forward is a biannual publication that celebrates the best of innovation and exploration. Through its pages we hope to inform and entertain, but also to encourage discussion about the most compelling developments taking place in the scientific and entrepreneurial world. Along the way, we’ll engage with the IP challenges that international organisations face every day.